CSPC Pharmaceutical Group Ltd
HKEX:1093
CSPC Pharmaceutical Group Ltd
Other Current Assets
CSPC Pharmaceutical Group Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Other Current Assets
¥776.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Assets
¥234.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Current Assets
¥7.1B
|
CAGR 3-Years
191%
|
CAGR 5-Years
109%
|
CAGR 10-Years
72%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Assets
¥1.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Assets
¥2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
24%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Other Current Assets
¥160.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
CSPC Pharmaceutical Group Ltd
Glance View
CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.
See Also
What is CSPC Pharmaceutical Group Ltd's Other Current Assets?
Other Current Assets
776.6m
CNY
Based on the financial report for Sep 30, 2024, CSPC Pharmaceutical Group Ltd's Other Current Assets amounts to 776.6m CNY.
What is CSPC Pharmaceutical Group Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
13%
Over the last year, the Other Current Assets growth was 18%. The average annual Other Current Assets growth rates for CSPC Pharmaceutical Group Ltd have been 23% over the past three years , 11% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet